Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Marc Katchen

Neurology Galesburg, IL Medical Doctor

NPI 1447266564 CMS profile 201199

765 N Kellogg St, Suite 207, Galesburg, IL 61401

Open in the dashboard

General payments

$2,874

33 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Marc Katchen of Galesburg, IL is reported in the CMS Open Payments database as having received $2,874 across 33 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 59th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $2,040 10
2023 General $196 3
2022 General $333 6
2021 General $134 3
2020 General $43 3
2019 General $128 8

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Marc Katchen
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Marc Katchen were reported at $0. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Marc Katchen Neurology median Middle half National median
2019 $128 $474 $118–$2,177 $163
2020 $43 $367 $82–$2,309 $114
2021 $134 $438 $104–$2,547 $132
2022 $333 $442 $103–$2,388 $149
2023 $196 $464 $119–$2,312 $160
2024 $2,040 $468 $119–$2,323 $164
2025 $0 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. LivaNova USA, Inc. $1,495 5 payments
  2. AbbVie, Inc. $249 3 payments
  3. Genzyme Corporation $231 2 payments
  4. Organogenesis Inc. $164 5 payments
  5. TG Therapeutics, Inc. $125 1 payment
  6. Argenx US, Inc. $123 2 payments
  7. Exact Sciences Corporation $118 1 payment
  8. AstraZeneca Pharmaceuticals LP $112 1 payment
  9. Novartis Pharmaceuticals Corporation $67 1 payment
  10. Avion Pharmaceuticals $63 4 payments
  11. Other $128 8 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $1,903 30 payments
  2. Travel and Lodging $971 3 payments
Products named General payments · program years 2019–2024
  1. VNS Therapy $1,495 5 payments
  2. QULIPTA $237 2 payments
  3. DUPIXENT $231 2 payments
  4. BRIUMVI $125 1 payment
  5. Puraply $121 2 payments
  6. Cologuard Collection Kit $118 1 payment
  7. AIRSUPRA $112 1 payment
  8. LEQVIO $67 1 payment
  9. Dhivy $63 4 payments
  10. VYVGART $63 1 payment
  11. Other $243 13 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 62 drugs

Part D claims

3,269

Median for Neurology: 833

Drug cost

$459,464

Median for Neurology: $202,670

Branded share of claims

19.7%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Rebif Interferon Beta-1a/Albumin Brand 13 $129,600
Austedo Xr Deutetrabenazine Brand 18 $70,707
Copaxone Glatiramer Acetate Brand 12 $70,410
Nurtec Odt Rimegepant Sulfate Brand 12 $22,405
Aimovig Autoinjector Erenumab-Aooe Brand 30 $22,210
Ubrelvy Ubrogepant Brand 13 $17,468
Rytary Carbidopa/Levodopa Brand 15 $15,240
Lacosamide Generic 72 $12,468
Bromocriptine Mesylate Generic 12 $9,433
Levetiracetam Generic 258 $8,455

The 10 drugs with the highest cost, of 62 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 22 billing codes

Paid by Medicare

$103,823

Medicare's payments for the services billed

Medicare patients

718

Average age 73

Services billed

1,225

370 women, 348 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 47%
Diabetes 29%
Chronic kidney disease 29%
Ischemic heart disease 23%
COPD 23%
Depression 22%
Atrial fibrillation 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

5 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
QULIPTA
  • AbbVie, Inc. $135
$135 — —
BRIUMVI
  • TG Therapeutics, Inc. $125
$125 — —
DUPIXENT
  • GENZYME CORPORATION $115
$115 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $112
$112 — —
VYVGART Hytrulo
  • ARGENX US, INC. $60
$60 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

33 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record